Background: Alcohol dependence (AD) shows evidence for genetic liability, but genes influencing risk remain largely unidentified.
A LCOHOL DEPENDENCE (AD) is a major public health burden with substantial costs for individuals and societies (Rice, 1999) . Despite robust evidence for genetic influences on risk (Cotton, 1979; Prescott et al., 2005a; Sigvardsson et al., 1996) and heritability estimates of 50% (Ystrom et al., 2011) , the genes influencing AD risk remain largely unidentified.
Prior genomewide association studies (GWAS) of AD and alcohol-related phenotypes in European samples detected novel signals in the PECR (Treutlein et al., 2009) , AUTS2 (Schumann et al., 2011) , and uncharacterized c15orf53 genes. None of these novel signals were replicated. Two independent signals were detected and replicated around the long-standing candidate gene ADH1B (Frank et al., 2012; Gelernter et al., 2014) . Three studies of Asian subjects identified signals at ALDH2 (Baik et al., 2011; Quillen et al., 2014) and the ADH1B functional variant H47R (rs1229984) (Park et al., 2013) , likely due to the frequencies of functional ADH and ALDH alleles in Asian populations.
To identify genes influencing alcohol-related phenotypes, we conducted a GWAS of AD. To maximize power, we studied an ethnically homogeneous sample of cases, affected siblings, and unscreened controls from Ireland, correcting for relatedness and lack of control screening analytically. We sought replication in 15,496 subjects of European descent (6,742 case/controls and 8,754 population samples).
Well-developed experimental approaches can test directly whether changes in candidate genes impact behavioral response to ethanol (EtOH) in vertebrate (Crabbe, 2002) and invertebrate (Grotewiel and Bettinger, 2015) model organisms (MOs). Orthologs of genes that affect simple EtOH responses in invertebrates also affect more complex EtOH responses in mammals, including measures of sensitivity and voluntary drinking (Bhandari et al., 2012; Kapfhamer et al., 2008; Liu et al., 2008) . This approach has previously been successful in demonstrating functional relevance of genes implicated by GWAS in EtOH-response behaviors (Schumann et al., 2011) .
To provide functional support for GWAS candidates, we tested whether perturbation of orthologous genes alters behavioral response to EtOH in Caenorhabditis elegans and/ or Drosophila, depending on the presence of orthologous genes and the availability of genetic reagents and information. In vertebrate MO, we analyzed correlations between candidate gene expression and alcohol phenotypes bioinformatically in curated archival data from recombinant inbred (BXD) mouse lines and we tested the effect of pharmacological antagonism of 1 candidate gene product on motivation to self-administer EtOH in rats after chronic EtOH exposure. For 1 candidate gene with no ortholog outside of primates, we tested for expression differences in alcohol-dependent and control human postmortem brain tissue stratified by clinical status or genotype.
MATERIALS AND METHODS

GWAS Discovery Sample
Participants in the Irish Affected Sib Pair Study of Alcohol Dependence (IASPSAD) were recruited in Ireland and Northern Ireland between 1998 (Prescott et al., 2005b . Briefly, probands were ascertained in community alcoholism treatment facilities and public and private hospitals. Probands were eligible for inclusion if they met DSM-IV criteria (American Psychiatric Association, 1994) for lifetime AD and if all 4 grandparents had been born in Ireland, Northern Ireland, Scotland, Wales, or England. Probands, siblings, and parents were interviewed by clinically trained research interviewers, most of whom had extensive clinical experience with alcoholism. We assessed lifetime history of AD using a modified version of the Semi-Structured Assessment of the Genetics of Alcoholism interview, version II (Bucholz et al., 1994) , demographic characteristics, other comorbid conditions, alcohol-related traits, personality features, and clinical records. All participants provided informed consent. We included 815 probands and siblings in genotyping.
A total of 2,048 DNA samples from healthy, unpaid volunteers donating blood at the Irish Blood Transfusion Service and obtained from the Trinity Biobank at Trinity College Dublin were used as controls. Biobank controls were eligible if they denied any problems with alcohol or history of mental illness and if all 4 grandparents had been born in Ireland, Northern Ireland, Scotland, Wales, or England. Because of the sample source, controls were not formally screened for AD, but the lack of screening was addressed analytically (see GWAS Statistical Analyses). Information about age and sex was available for these subjects.
GWAS Genotyping, Quality Control, and Imputation
Genomic DNAs passing quality control (QC) standards were genotyped on Affymetrix v6.0 SNP arrays (Affymetrix, Santa Clara, CA). All arrays included in analysis passed standard QC measures. Genotypes were called using BEAGLECALL (Browning and Yu, 2009) , followed by rigorous genotype QC. We imputed the 1000 Genomes Project (1000 Genomes Project Consortium, 2010) April 2012 integrated variant reference panel of 36.5 million simple nucleotide polymorphisms (SNPs) using IMPUTE2 (Howie et al., 2009 ). We converted posterior genotypic probabilities to allelic dosages using GenABEL (Aulchenko et al., 2007) . After postimputation QC, 8,344,348 SNPs were available for analysis. Complete details of array, SNP and individual QC, BEAGLECALL genotyping, imputation, and postimputation QC and sample power are included in Appendix S1 and Figs S1-S4.
GWAS Statistical Analyses
We tested individual SNPs for association by Modified QuasiLikelihood Score (MQLS) (Thornton and McPeek, 2007) because MQLS accepts genotypes in postimputation dosage format and can account for subject relatedness by using a kinship matrix calculated from pedigree data. Unscreened Biobank controls were coded as phenotype unknown. We included an estimated sex-weighted 8.9% population AD prevalence derived from population (Hasin et al., 2007) and unpaid Dutch blood donor (Atsma et al., 2011) data to account for lack of control screening. Varying this estimate from 0% to 12% gave a similar p-value distribution for all prevalence estimates. MQLS cannot include covariates. We used a threshold of p ≤ 5 9 10 À8 for genomewide significant (GWS) results. Odds ratios were not calculated due to the nonindependence of related case alleles. Secondary analytic approaches for gene-based, network, and geneset analyses are described in Supplementary Methods in Appendix S1.
Selection for Further Study
We calculated false discovery rate (FDR) q-values (Storey and Tibshirani, 2003) for all SNPs to select loci for further study. For replication and secondary analysis of discovery data, we used a threshold q < 0.3 (p < 1 9 10 À5 for our p-value distribution, 30% of results are false discoveries) to maximize discovery potential. For functional studies, we included any loci achieving GWS signals in discovery or replication (COL6A3, LOC339975) and any loci with both q < 0.1 (10% of results are false discoveries) and prior evidence of involvement in EtOH phenotypes from human and/or MO studies (KLF12, RYR3).
Assessment of Variants for Potential Functional Impact
For variants with q < 0.1, we assessed variant potential to impact function either directly or via linkage disequilibrium (LD) with other variants using GWAS3D (Li et al., 2013) . GWAS3D provides an adjusted p-value from Fisher's combined probability test incorporating the GWAS evidence of genetic association with evidence that the variant alters (i) coding or (ii) conserved sequence, or (iii) sites of long-range interactions, (iv) binding energy for known transcription factors or lies within (v) promoter, (vi) enhancer, or (vii) insulator elements from ENCODE and other published sources.
GWAS Replication
We conducted replication analyses in N = 15,496 European subjects from 3 AD case-control samples (Edenberg et al., 2010; Frank et al., 2012; Gelernter et al., 2014; Treutlein et al., 2009 ) and 1 population sample . Details of the individual samples, genotyping, and imputation are provided in Appendix S1. We conducted look-up analysis of replication SNPs in each sample and meta-analysis of all replication SNPs first in the 4 ascertained casecontrol samples, then adding the unascertained population sample, for which AD diagnoses were derived rather than directly assessed , using METAL (Willer et al., 2010) . We weighted meta-analyses by sample size and direction of effect because MQLS does not generate standard errors. Many markers are nonindependent due to LD, so we assessed the 274 replication SNPs for independence using SNAP (Johnson et al., 2008) to determine the number of independent tests.
Invertebrate MO Studies
C. elegans Studies. A single, continuous acute exposure of C. elegans to 400 mM exogenous EtOH yields an internal concentration of 40 to 50 mM ) (~200 mg/dl, within the range observed in humans after heavy drinking (Bond et al., 2010) ). A concentration-dependent slowing of locomotion at 10-minute exposure (measuring initial sensitivity) is followed at~30 minutes by an increase in speed of locomotion (measuring AFT) (Davies et al., 2003 (Davies et al., , 2004 despite an increase in the internal tissue concentration of EtOH . Both measures can be independently affected by the loss of individual genes Bhandari et al., 2012; Davies et al., 2003 Davies et al., , 2004 Kapfhamer et al., 2008; Mathies et al., 2015) .
C. elegans Strains-C. elegans strains were maintained as previously described (Brenner, 1974) . Strains used in these studies were wild-type N2 (var. Bristol), RB1603 klf-3(ok1975), TR2170 unc-68 (r1161), and TR2171 unc-68(r1162).
RNAi Treatment-RNA interference (RNAi) induction and locomotion assays were performed as previously described (Kamath et al., 2001) . Briefly, cultures of bacteria containing RNAi vectors corresponding to genes C16E9.1, C18H7.1, cutl-23, or empty vector (L4440) (Geneservice, Cambridge, UK) were plated on nematode growth media (NGM) plates with 1 mM IPTG, and allowed to grow at room temperature for 24 hours. Three to 5 fourth larval stage wild-type N2 worms were placed on the seeded plates and incubated at 20°C and allowed to produce F1 progeny, which were maintained on RNAi cultures to adulthood. First-day adult F1 progeny were collected and subjected to behavioral analysis.
Locomotion Tracking-Locomotion was assayed as previously described . Ten worms for each strain were tested in each assay, and we calculate the average of the speeds of the 10 worms in each iteration of the assay (n = 1). Comparisons were only made of animals tested simultaneously on the same plates. Briefly, NGM-containing plates were dried for 2 hours with lids off at 37°C, and then, copper rings were embedded in the surface of the plate to act as corrals. EtOH was added to the plates to a final concentration of 0 or 400 mM, the plates were sealed, and the EtOH was allowed to equilibrate for 2 hours. Worms were placed in the corrals and 2-minute movies were captured at 10 and 30 minutes of exposure using a Retiga 4000R camera (QImaging, Surrey, BC, Canada) on an Olympus SZX-7 microscope (Center Valley, PA). Movies were analyzed using ImagePro Plus (6.2) (MediaCybernetics, Rockville, MD) software. We derived 2 measures of EtOH response: initial sensitivity (depression of speed of locomotion at 10-minute exposure compared to the same strain untreated) and AFT (increase in speed at 30-minute exposure compared to the same strain at 10 minutes).
Statistical Analysis-Comparisons were made of animals tested in identical conditions. Relative speeds (treated/untreated 9 100) were used in comparisons. We used Prism 5.0 software (GraphPad, La Jolla, CA) to perform 2-way ANOVA comparisons across time of EtOH exposure and genotype with Bonferroni post hoc comparisons at each time point to determine differences between genotypes. Development of AFT was tested using a paired 2-tailed t-test. Drosophila Studies. Only 1 candidate locus (RYR3) had both a Drosophila ortholog and genetic reagents available. Detailed methods for Drosophila studies are provided in Supplementary Materials and Methods in Appendix S1.
Mammalian MO Studies
Mouse Studies. We queried selected candidate genes for localization to EtOH behavioral quantitative trait locus (QTL) intervals using the Mouse Genome Informatics (MGI) tool set. We queried published expression microarray and EtOH behavioral response data sets within the curated GeneNetwork web-based resource of genetic, phenotypic, and genomic data for evidence that basal candidate gene expression correlated with measured EtOH behavioral phenotypes in C57BL/6J 9 DBA/2J BXD mouse lines. All expression data were from Affymetrix M430 microarrays (Affymetrix, Santa Clara, CA). We included saline or air-treated BXD control whole brain (GN113), nucleus accumbens (NAc) (GN156), prefrontal cortex (PFC) (GN135), and ventral tegmental area (VTA) (GN228) (Wolen et al., 2012) .
We used the single Col6a3 probeset (1424131_at_A). We selected the most representative probeset based on GeneNetwork quality scores for Ryr3 (1427427_at_A) and Klf12 (1455521_at; we also assessed the better of the 2 probesets showing Klf12 EtOH response (Wolen et al., 2012) , 1439847_s_at). Robust multi-array average normalized expression data were used for Spearman rank correlation analyses with EtOH behavioral phenotypes. Identifiers of probesets and phenotypes used for specific analyses are shown in Results and in Fig. 5 . Expression and phenotype data archived in GeneNetwork were produced in different laboratories and at different times; as a result, the N of BXD lines tested in our analyses varies across the tissues and phenotypes analyzed. We use the GeneNetwork default setting to retrieve the top 1,000 correlations for each probeset 9 tissue pair.
A total of 5,134 traits are present in GeneNetwork, but they are not all independent because of both the multiple related measures made within studies and the partial overlap of BXD lines used between studies. GeneNetwork developers suggest that Bonferroni correction for 200 independent traits approximates an FDR of 0.2 based on data in (Wang et al., 2016) ). We apply a more stringent correction for 2,000 independent tests to maintain a conservative significance threshold of 0.05/2,000 = 2.5E-05.
Rat Studies. We studied the effect of pharmacological antagonism of ryanodine receptors on EtOH self-administration in rats. Detailed methods for this single rat study are provided in Supplementary Materials and Methods in Appendix S1.
Human Postmortem Studies
PFC and NAc tissues from 41 AD cases and 41 controls were provided by the New South Wales Tissue Resource Centre. Age, sex, ethnicity, brain weight, brain pH, postmortem interval (PMI), tissue hemisphere, cause of death, blood toxicology, smoking status, neuropathology, and liver pathology were provided for each subject. Confounding effects of all these covariates were controlled by analysis of covariance (ANCOVA ;  Table S7 ). Total RNA was isolated from 100 mg frozen tissue using the mirVana-PARIS kit (Life Technologies, Carlsbad, CA) following manufacturer's protocols. RNA concentration was measured using the Quant-iT Broad Range RNA Assay kit (Life Technologies). The RNA integrity number (RIN) was measured on the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA). Quantitative real-time PCR (qRT-PCR) analyses were performed as previously described using SYBR Green (Riley et al., 2010) with primers spanning the LOC339975 exon 2 to 3 junction. Samples with missing genotypes and outliers (AE2 standard deviations [SD] from the mean) were omitted from further analysis.
RESULTS
Irish Case/Control Discovery Data Set
After all QC, the data set consisted of 706 probands and affected siblings, 464 (65.7%) male and 242 (34.3%) female, mean age 41.8 (SD 9.8) years, and 1,748 population controls, 755 (43.2%) male and 993 (56.8%) female, mean age 37.2 (SD 12.6) years, with 8,344,348 SNPs for analysis. The Manhattan plot for case/control analysis of AD is shown in Fig. 1 . The QQ plot for the final data set after imputation and all QC is shown in Fig. 2 .
Variation in COL6A3 is Associated with AD
In single marker analyses, 14 SNPs defining 2 independent genomic intervals achieve genomewide significance, 13 within the collagen VI A3 (COL6A3) gene on chromosome 2q37.2 (Fig. 3A) , including the most significant SNP in our study, rs2256485, p = 6.17 9 10 À9 (Table 1) . COL6A3 encodes an extracellular matrix (ECM) protein expressed in brain. Although there is no prior human association evidence for this gene, remodeling of the ECM has been strongly implicated in response to various drugs of abuse (Lubbers et al., 2014) . The second interval is defined by a single SNP (rs150268941, p = 1.65 9 10 À8 , Table 1 ) on chromosome 3q26.31 (Fig. S5A ).
Additional Loci are Suggestively Associated with AD
A total of 28 SNPs in 7 LD-independent loci had q < 0.1 (Table 1) If the Fisher's combined probability test from GWAS3D provided increased evidence based on potential function of the test SNP or a SNP in LD with the test SNP, the combined p-value is also shown in Table 1 . Of the 28 SNPs with q < 0.1 input to GWAS3D, 14 showed more significant combined p-values after incorporating evidence of function. Of these 14 results, 12 were based on evidence of functional impact for the GWAS target SNP itself. For the 2 sites where the increased evidence was based on putative functional impact of a variant in LD with the GWAS signal, the LD SNP rsID, r 2 with the GWAS target and functional evidence are shown. GWAS3D analysis yields strongly enhanced signals in COL6A3 (rs2646265: p = 1.47 9 10 À8 , combined p = 1.40 9 10 À12 ; rs2256485: r 2 =1 with rs2646265, p = 6.17 9 10
À9
, combined p = 6.18 9 10
À13
) and RYR3 (rs4780153:
.867 with rs2076954, p = 1.47 9 10
À7
, combined p = 7.92 9 10
À10
). The signals at 3q26.31 ( Fig. S5A ) and KLF12 ( Fig. 3C ) are with single imputed SNPs of low minor allele frequency (MAF). In 1000 Genomes Phase 3 data from U.K. subjects (GBR, British residents of England and Scotland), rs117695261 (MAF 0.03) in KLF12 has no r 2 >0.2 with any other SNP, consistent with the lack of correlated signals in Irish subjects. By contrast, rs150268941 on 3q26.31 is tagged by rs148750402, which was imputed and analyzed in our sample (0.034, p = 0.00147, q = 0.754464). Direct genotyping of rs150268941 also did not support the observed association (see Appendix S1), and we did not consider the chromosome 3q26.1 region further.
Human Replication
A total of 274 SNPs had discovery q < 0.3, and were included in replication. SNAP analysis indicated that 121 represent LD-independent tests, setting replication significance at 0.05/121 = 0.0004. Lookup replication and metaanalysis results arranged by chromosome and base pair are also shown for all 28 SNPs with q < 0.1 in Table 1. Table S1 shows these results for all 274 SNPs with q < 0.3. No individual SNP achieved p < 0.0004 in any sample. In metaanalysis of the 4 case-control samples, 1 SNP in a second novel locus, the long noncoding RNA (lncRNA) gene LOC339975 showed a GWS signal (chr. 4q35.2, rs11726136, p = 7.52 9 10 À7 , q = 0.149 in the discovery sample, Fig. 3D , and GWS p = 4.20 9 10 À8 in meta-analysis of the 4 case/ control samples, Table 1 and Table S1 ). Because of differences in ascertainment and severity of affection, we performed replication analyses including the Australian population sample separately; this signal was not significant when the Australian sample was included (Table S1) .
We also assessed evidence in our discovery data for association with loci identified in prior AD GWAS in subjects of European ancestry. We detect modest signals in PECR (minimum p = 0.0017), AUTS2 (minimum p = 0.0009), and ADH1B (minimum p = 0.00166), but none of these signals are with the SNPs originally reported (Table S2) . We detect no evidence of signal in c15orf53 (minimum p = 0.2058).
Secondary Analyses
Results of secondary analyses of discovery GWAS data are shown in Table S3 (gene-based analyses), Fig. S6 and , q = 0.00016), RYR3 (p = 2.62 9 10 À7 , q = 0.0029), and LOC339975 (p = 5.31 9 10
À6
, q = 0.0248) (Table S3) .
Selection for Functional Studies
We undertook functional studies of 4 candidate loci, COL6A3, and LOC339975 based on the GWS signals in discovery or replication analyses and KLF12 and RYR3 based on discovery q < 0.1 and prior evidence of implicating these loci in alcohol-related phenotypes (reviewed below). We used established behavioral paradigms to test orthologs of COL6A3, KLF12, and RYR3 for effects on behavioral responses to EtOH in C. elegans and Drosophila where orthologous genes were present in the models and genetic reagents and information were available. We analyzed correlation between brain gene expression and alcohol-related phenotypes in BXD mouse data for all 3 genes. All these studies are summarized in Table 2 , and we report here the results of all studies performed. We additionally tested the effect of the ryanodine receptor antagonist dantrolene on EtOH self-administration in rats. The fourth gene, LOC339975, is primate-specific and was taken forward for study in human postmortem brain.
COL6A3: Regulation of EtOH Sensitivity in C. elegans and Correlation with Handling-Induced Convulsions in Mice
We tested 3 C. elegans genes with equally high orthology to human COL6A3 for effects on initial sensitivity and AFT. RNAi knockdown of C16E9.1 decreased initial sensitivity compared to control RNAi animals (p < 0.05, Fig. 4A ) but did not affect the development of AFT. RNAi knockdown of the other COL6A3 orthologs (C18H7.1 and cutl-23) produced no significant differences in either measure (Fig. 4B,C) . Statistics and uncorrected basal speed data for all C. elegans experiments are shown in Table S6 .
In mice, Col6a3 is located within the Alcw5 QTL interval (MGI:3037048) for handling-induced convulsions (HIC) following 72-hour EtOH vapor exposure (Bergeson et al., 2003) . The Alcw5 QTL maps to 39.16 centiMorgans (cM) on mouse chromosome 1, with a support interval of 28 to 47 cM. After converting cM to megabase pairs (Mb) for the latest version of the mouse genome (GRCm38/mm10), this yields a physical location of the Alcw5 QTL peak of 75.57 Mb and a QTL support interval of 62.12 to 107.66 Mb. Col6a3 is located at mouse chr1:90766860-90843971, within the defined Alcw5 QTL support interval.
In GeneNetwork, the strongest correlation observed for mouse Col6a3 basal whole brain expression (GN113, probeset 1424131_at_A) is with total HIC score (sum of baseline subtracted HIC at 4, 6, and 7 hours) after 4 g/kg IP EtOH in males (Philip et al., 2010 ) (trait 11,382, correlation rank = 1, rho = 0.959, p = 1.05 9 10 À9 , N = 13 strains, Fig. 5A ), which surpasses our Bonferroni-corrected significance level of p = 2.5 9 10
À5
. HIC at 7 hours in males (trait 11,380, correlation rank = 2, rho = 0.835, p = 3.11 9 10 À6 , N = 18 strains) and in males and females (trait 11,894, correlation rank = 3, rho = 0.780, p = 5.11 9 10 À5 , N = 18 strains) (Philip et al., 2010) are also strongly correlated with Col6a3 expression, and all 3 HIC measures are highly correlated (phenotypic rho = 0.91 to 0.95). Col6a3 expression correlated negatively with 2-bottle choice EtOH preference (Phillips et al., 1994) (trait 10,479, correlation rank = 67, rho = À0.569, p = 0.0124, N = 18 strains, Fig. 5B ). While this is not significant after multiple test correction, it is consistent with the expectation that factors increasing HIC will decrease voluntary consumption (Metten et al., 1998) .
KLF12: Regulation of AFT to EtOH in C. elegans and Gene Expression Correlation with Locomotor Activity in Mice
There is significant prior evidence for a role of KLF12 in EtOH-response behaviors across species. In BXD mice, Klf12 is regulated by acute EtOH in PFC, NAc, and VTA, and is a hub in a network of EtOH-responsive genes (Wolen et al., 2012) . In humans, KLF12 acts in combination with the co-repressor CTBP1 (Schuierer et al., 2001) , and in C. elegans, the ctbp-1 gene is required for the development of AFT . The closest C. elegans ortholog to human KLF12 is klf-3, and this evidence collectively suggests KLF-3 is likely to act together with CTBP-1 to regulate AFT in worms.
We tested a strong loss-of-function allele in klf-3. There was no difference in initial sensitivity between wild-type N2 and klf-3(ok1975) mutants (Fig. 4D) . While wild-type N2 animals demonstrated normal AFT at 30 minutes, klf-3 mutants failed to develop AFT (Fig. 4D , t-test of degree of speed recovery between 10 and 30 minutes, 400 mM EtOH: N2 versus klf-3(ok1975), t 3 = 8.99, p < 0.001). These data strongly suggest that the transcriptional regulation provided by KLF-3 is required for the development of AFT in worms.
Based on patterns of regulation of mouse Klf12 by EtOH (Wolen et al., 2012) , we analyzed correlation between basal Klf12 expression in mouse PFC (GN135), NAc (GN156), VTA (GN228), and whole brain (GN113) data sets and BXD panel phenotypes in GeneNetwork. The strongest correlations observed for basal Klf12 expression in PFC (GN135, probeset 1455521_at) were with locomotor activity 0 to 5 minutes (trait 11,708, correlation rank = 1, rho = 0.756, p = 1.69 9 10 À5 , N = 22 strains, Fig. 5C ) and 0 to 20 minutes (trait 11,705, correlation rank = 3, , N = 22 strains) after 2.25 g/ kg IP EtOH in females (Philip et al., 2010) . The first result remains significant, and the second falls just below significance after Bonferroni correction. Basal Klf12 expression in mouse NAc (GN156, probeset 1439847_s_at) was positively correlated with AFT (Kirstein et al., 2002 ) (trait 10,348, correlation rank = 29, rho = 0.560, p = 0.003, N = 25 strains, Fig. 5D ). While not significant after Bonferroni correction, this is consistent with the failure to develop AFT in C. elegans klf-3 mutants.
RYR3: Regulation of Initial Sensitivity to EtOH in C. elegans, Rapid Tolerance to EtOH in Drosophila, and Motivation to Self-Administer Alcohol in Rats
Previous studies have implicated ryanodine receptors (RyR) in EtOH phenotypes: In humans, RYR3 was implicated in a GWAS of alcohol response (Joslyn et al., 2010) . Ryr1 and Ryr2 up-regulation in mouse brain is observed following acute exposure to multiple drugs including alcohol (Kurokawa et al., 2010 (Kurokawa et al., , 2013 and behavioral changes like conditioned place preference and withdrawal expected following acute exposure are blocked by the RyR antagonist dantrolene (Kurokawa et al., 2010 (Kurokawa et al., , 2013 .
C. elegans has 1 RyR gene, unc-68. We tested the effect of EtOH on 2 strains carrying different unc-68 mutations (r1161 and r1162). Loss of unc-68 confers reduced sensitivity to EtOH (minimum p < 0.001 for r1162, Fig. 4E, F) . We also observed consistent effects of mutations in 2 additional genes with products involved in calcium regulation and known to interact with UNC-68 (Supplementary Materials and Methods, Supplementary Results, and Fig. S7 in Appendix S1).
There is a single RYR3 ortholog in Drosophila, RyR. We found that 2 insertional mutations that cause partial loss of function in RyR reduce the development of rapid tolerance to EtOH with no obvious effects on initial sensitivity (Supplementary Materials and Methods, Supplementary Results and Fig. S8 in Appendix S1).
The mouse Ryr3 gene is localized to the support intervals for a complex group of EtOH behavioral QTL mapped to Chr 2 but Ryr3 basal whole brain expression (GN113; probeset 1427427_at) is not strongly correlated with EtOH-related phenotypes.
The availability of dantrolene, a pharmacological antagonist of ryanodine receptors, allowed us to assess the effect of antagonism of RyRs on the complex behavior of EtOH self-administration in rats. We found that in rats, dantrolene dose dependently reduced motivation to self-administer EtOH after 50 contiguous days of chronic EtOH self-administration (Supplementary Materials and Methods, Supplementary Results, and Fig. S9 in Appendix S1). (E, F) unc-68 mutant animals demonstrate reduced sensitivity to EtOH relative to wild-type N2. Statistical significance is shown for 2-way ANOVA followed by post hoc comparisons across genotypes (*p < 0.05, **p < 0.01).
alleles at rs11726136, we therefore tested AD case and control postmortem tissue from PFC and NAc for differences in LOC339975 expression by clinical status or genotype. The final numbers available for analysis were for PFC, 28 cases and 30 controls and 50 reference allele T/T and 5 T/G genotypes, and for NAc, 34 cases and 35 controls and 58 T/T and 7 T/G genotypes (Table S7) .
We included age, sex, ethnicity, brain weight, brain pH, PMI, tissue hemisphere, cause of death, blood toxicology, smoking status, neuropathology, and liver pathology as covariates in analysis. Neuropathology and brain weight were both significantly associated with expression level in the NAc; no covariates were associated with expression level in the PFC (Table S7) . We detected no difference in expression level between AD cases and controls in either NAc (p = 0.75) or PFC (p = 0.23) (Fig. 6A,B and Table S7A,B) . After controlling for covariates, expression of LOC339975 is significantly reduced in carriers of the associated nonreference allele in NAc (p = 0.003, Fig. 6C , Table S7C ) but did not differ by genotype in PFC (p = 0.54, Fig. 6D , Table S7D ). Alternative regulation in NAc and PFC is consistent with the presence of several distinct transcription factor binding sites upstream of lncRNA genes (Alam et al., 2014) . Although we do not detect case/control differences in expression, our data suggest the associated allele of rs11726136 has functional consequence based on the reduced Fig. 5 . Bioinformatic analysis of correlation of Col6a3, Klf12, or Ryr3 expression with ethanol (EtOH) behaviors in C57BL/6J x DBA/2J recombinant inbred (BXD) mouse lines. The GeneNetwork (GN) web-based analysis platform was used to identify correlations between basal expression levels of Col6a3, Klf12, or Ryr3 and EtOH behaviors. Panels A-D display Spearman ranked order correlations between microarray gene expression (x-axis) and behavioral phenotypes (y-axis). Col6a3 (probeset 1424131_at) in GN113 whole brain expression data set showed significant positive correlation with total handling-induced convulsion (HIC) score (sum of baseline subtracted HIC at 4, 6 and 7 hours) after 4 g/kg intraperitoneal (IP) EtOH in males (GN record 11382; Panel A) and negative correlation with EtOH 2-bottle choice voluntary consumption (GN record 10479; Panel B). Klf12 basal expression in prefrontal cortex (GN135, probeset 1455521_at) was significantly positively correlated with locomotor activity 0 to 5 minutes after 2.25 g/kg IP EtOH (GN record 11708; Panel C) and in nucleus accumbens (GN156, probeset 1439827_s_at) was positively correlated with EtOH acute functional tolerance (GN record 10348; Panel D).
LOC339975 expression observed in the NAc in heterozygotes.
DISCUSSION
We identified 2 novel GWS association signals in COL6A3 and LOC339975, and suggestive signals in a number of loci, including 2 genes with prior support, KLF12 and RYR3. COL6A3, RYR3, and LOC339975 are further supported by gene-based analyses (Table S3) . We detect evidence of human replication only for LOC339975 but we observe consistent evidence across multiple MOs that COL6A3, KLF12, and RYR3 orthologs modulate behavioral response to EtOH. Human postmortem studies show that the AD-associated allele reduces LOC339975 expression in NAc.
Collagen VI A3 (COL6A3)
Collagen IV (Joslyn et al., 2010) and VIII (Edenberg et al., 2010) genes were implicated in EtOH response and AD. COL6A3 is located in a QTL interval for alcohol withdrawal identified in the IASPSAD sample (Kuo et al., 2006) . Although this signal did not replicate, our GWS association with potentially functional SNPs (GWAS3D results, Table 1 ) is supported by the reduced sensitivity after RNAi knockdown in C. elegans (Fig. 4A) , mapping to the Alcw5 QTL for HIC in mice and the strong correlation between expression and HIC in BXD lines (Fig. 5A ). COL6A3 encodes a component of the ECM, and there is mounting evidence (Lubbers et al., 2014 ) that multiple substances of abuse increase ECM remodeling and that remodeling is required for the expected behavioral changes following exposure. EtOH dose dependently induces tissue plasminogen activator (tPA), required for ECM remodeling, which enhances EtOH reward (Bahi and Dreyer, 2012) . Withdrawal seizures are reduced in tPA-deficient mice following chronic EtOH administration (Pawlak et al., 2005) . Inhibition of proteolytic enzymes that degrade the ECM block escalated responding during acute withdrawal in dependent animals (Smith et al., 2011) . Collectively, these results argue that ECM structural components (like COL6A3) and remodeling enzymes are important determinants of EtOHinduced neuroadaptation. We hypothesize that Col6a3 may underlie the Alcw5 HIC QTL.
Krueppel-Like Factor 12 (KLF12)
Klf12 is regulated by acute EtOH in mouse brain and is a hub in a network of EtOH-responsive genes (Wolen et al., 2012) including many implicated in EtOH response (e.g., Grm3 (Gass and Olive, 2008) , Kcnma1 (Davies et al., 2003) , and Gsk3b (French and Heberlein, 2009) ). Orthologs of KLF12 (Fig. 4D ) and its binding partner CTBP1 are required for the development of AFT in C. elegans. The targets of KLF12 regulation are not yet known, but the convergent evidence argues strongly they are central to acute EtOH response and potentially relevant to AD risk.
Ryanodine Receptor 3 (RYR3)
RYR3 was implicated in a GWAS of EtOH response (Joslyn et al., 2010) and our observed association may be driven by functional SNPs (GWAS3D analysis, Table 1 ). In C. elegans, loss of the single RyR gene unc-68 reduces initial sensitivity to EtOH (Fig. 4E,F) . This mutation would be predicted to decrease intracellular Ca
2+
. Consistent with this observation, we found that mutations in csq-1, which would be predicted to increase intracellular Ca 2+ concentration, increase initial sensitivity (Fig. S7A) . Mutations in the ether-a-go-go-related potassium channel gene unc-103, which has a genetic interaction with unc-68, also decrease sensitivity to EtOH (Fig. S7D) . In Drosophila, reduction in function of the RyR gene blunts rapid tolerance (Fig. S8B) .
The RyR antagonist dantrolene reduces cocaine (Kurokawa et al., 2011) and methamphetamine (Kurokawa et al., 2010) induced conditioned place preference, EtOH withdrawal symptoms (Kurokawa et al., 2013) , and motivation to self-administer EtOH after chronic exposure in a dose-dependent manner in rats (Fig. S9 ), but these studies are limited by the nonspecificity of dantrolene, an antagonist of both ryanodine and inositol triphosphate receptors, the latter functioning upstream of RyR activation. In myocytes, RyRs provide the Ca 2+ ions that activate BK channels (Lifshitz et al., 2011) , which have strong effects on EtOH response in vivo and in vitro (Davies et al., 2003; Martin et al., 2008) . EtOH modulates BK channel function in a calcium-dependent manner (Liu et al., 2008) , and we hypothesize that RyRs may be involved in this calcium-dependent modulation of BK channel function.
lncRNA LOC339975
lncRNA are of emerging importance in the function and dysfunction of the brain (Roberts et al., 2014) . Expression of the estimated 25 to 50K lncRNA genes in the human genome (Hangauer et al., 2013 ) is widespread in the brain and highly regulated (Guttman et al., 2011; Mercer et al., 2008) . lncRNA are implicated in multiple neurodevelopmental, neurodegenerative, and neuropsychiatric diseases, including schizophrenia (Barry et al., 2014 ), Alzheimer's (Faghihi et al., 2008) , autism (Kerin et al., 2012) , and neuronal excitability and epilepsy (Barry et al., 2017) . A recent GWAS of AD detected GWS association in the lncRNA LOC100507053 . While this signal is part of the larger ADH gene cluster signal reported and associated SNPs could only be analyzed in African Americans due to MAF or imputation information, LOC100507053 is anti-sense to multiple ADH genes, and has potential to regulate their expression. Although the role of these transcripts remains unclear, the growing number of reported associations argues that lncRNA genes are also important in human health and disease. Our data suggest the associated allele of rs11726136 may have functional consequence based on the reduced LOC339975 expression observed in the NAc.
Limitations
Unscreened controls: While the use of unscreened controls is common in studies of traits with low population prevalence, unscreened controls are not ideal for traits with the high population prevalence of AD (Wellcome Trust Case Control Consortium, 2007) . However, the most likely impact of this lack of screening is for a proportion of controls to be unrecognized and phenotypically misclassified cases. This will reduce the contrast between cases and controls, increase type II error and reduce study power to detect effects. Importantly, the use of unscreened controls is not expected to increase type I error and produce spurious positive results.
Lack of strong human replication: The lack of strong human replication is a serious limitation of our study. However, nonreplication of novel signals is common in GWAS of AD and may have several causes. Specific to our study, differences in sampling, data production, QC, imputation, or analysis can confound meta-analysis. The GESGA sample was imputed to an older, smaller HapMap reference panel, has many missing data points, and shows the least consistent sign tests (Table 1 and Table S1 ). The OZALC population sample was genotyped at multiple sites, a well-known source of systematic genotype bias. We note that our strongest replication signals come from analyses of the 3 samples (Irish, COGA, and Yale/Penn) with the most consistent ascertainment and genotyping. More generally, this pattern of nonreplication may reflect the multiple independent domains of risk for AD (Kendler et al., 2012) , including variation in (i) alcohol-specific physiological measures like initial sensitivity and tolerance (Schuckit et al., 1997) , (ii) brain reward circuitry implicated in substance use and other pathological behaviors (Volkow et al., 2012) , and (iii) personality traits like internalizing and externalizing behaviors (Harford et al., 2013) , which are unlikely to be influenced by the same genes. As in other complex traits, these issues will be overcome primarily by increasing sample size and power. Finally, as both KLF12 and RYR3 were previously implicated in substance phenotypes, our findings may be considered as replication evidence for these signals.
Limited phenotypic consilience: Across our MO studies, many different phenotypes are affected by manipulation of candidate orthologs, with little consilience between species. Although mammalian and invertebrate nervous systems show extensive molecular and functional conservation (Bargmann, 1998; Brownlee and Fairweather, 1999) and many drugs mediate their behavioral effects through orthologous target proteins (Kaletta and Hengartner, 2006; Matthews and Kopczynski, 2001) , phenotypic consilience and consistent direction of effect following manipulation of a specific gene are not always observed across species (e.g., manipulations of chloride intracellular channel 4 (Clic4) orthologs altered sensitivity in flies and mice but in different directions (Bhandari et al., 2012) . There are also differences in EtOHresponse measures available for different MOs (e.g., AFT has not been demonstrated in flies despite direct efforts to elicit this response (Chan et al., 2014) ). Within species, we observe consilience across studies for effects of (1) Klf-3 and binding partner Ctbp1 on AFT and (2) genes influencing intracellular calcium levels on initial sensitivity in worms, and (3) Col6a3 on HIC in mice.
CONCLUSIONS
Our combined data implicate COL6A3, KLF12, RYR3, and LOC339975 in response to EtOH across multiple species and/or AD risk in humans. Our data are also consistent with prior work implicating remodeling of the ECM (COL6A3), regulation of EtOH-responsive genes (KLF12), and regulation of intracellular calcium release (RYR3) in response to EtOH.
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